A Study to Evaluate the Safety and Tolerability of Tecarfarin in Healthy Chinese Volunteers

An Open-label, Phase 1, Sequential Cohort, Single-Dose Escalation Study to Assess the Safety and Tolerability of Tecarfarin (ATI-5923) in Healthy Chinese Volunteers

The purpose of the study is to evaluate the safety and tolerability of a single dose of tecarfarin in healthy Chinese Volunteers. the Pharmacokinetic and pharmacodynamic profile of tecarfarin will also be evaluated.

Study Overview

• Status: Completed
• Conditions: Pharmacokinetic and Pharmacodynamic Profile of Tecarfarin
• Intervention / Treatment: Drug: Tecarfarin 10mg; Drug: Tecarfarin 20mg; Drug: Tecarfarin 30mg; Drug: Tecarfarin 40mg

• Study Type: Interventional
• Enrollment (Actual): 40
• Phase: Phase 1

Contacts and Locations

Study Locations

• Hong Kong
  • Hong Kong, Hong Kong, 000000
    • HKU Phase 1 Clinical Trial Centre, The University of Hong Kong

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 55 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Subject must voluntarily sign and date an informed consent form, approved by the Institutional Review Board (IRB), prior to the initiation of any study-specific procedure.

2. Healthy Chinese* volunteers aged between 18 and 55 years inclusive, at the time of Screening

   *Definition of "Chinese": Subject is a Han Chinese who born in China (including Hong Kong) with Han Chinese parents and grandparents who born in China (including Hong Kong).

3. Body Mass Index (BMI) ≥19 and ≤ 24 kg/m2
4. Subject has been a non-smoker or has not used tobacco or nicotine-containing products for at least 3 months before Screening and prior to Day 1.

5. Subjects are in general good health with no history of significant diseases and no clinically significant abnormal findings based upon the results of physical examination, 12-lead ECG, laboratory safety tests and vital signs at screening and prior to dosing.

   • Vital signs (measured in a sitting position for at least 5 minutes) include tympanic temperature [T], pulse rate [PR], respiratory rate [RR], and blood pressure [BP]).

6. Female subjects must be non-pregnant, non-lactating or either postmenopausal for at least 2 years or surgically sterile (e.g., hysterectomy, bilateral oophorectomy, bilateral tubal occlusion or ligation) for at least 6 months. For female subjects of child bearing potential, they need to consentient to use appropriate contraceptive methods (abstinence, intrauterine device, diaphragm with spermicide, use by partner of a condom with spermicide) at least 28 days prior to and after dosing. Use of oral contraceptive and implantation of contraceptive methods by female subjects are not acceptable.

7. Male subjects who have female partners of reproductive potential must either:

   • Abstinence from sexual intercourse during Day -1 to Day 28, or
   • Use an approved method of contraception (which may include use of a condom with spermicide or use by partner of oral, implantable or injectable contraceptives, intrauterine device, diaphragm with spermicide) during Day -1 to Day 28.
   • Refrain from sperm donation during Day -1 to Day 28.
8. Able and willing to follow instructions and to comply with protocol requirements.

Exclusion Criteria:

1. Positive test results for HIV, syphilis antibody, hepatitis B surface antigen (HBsAg), or hepatitis C antibody (HCV Ab) at Screening.
2. Positive tests for alcohol breathalyzer or urine drugs of abuse at Screening or Day -1 or a history of drug abuse/dependence.
3. Use of tobacco or nicotine products 3 months before screening and prior to Day 1.
4. Heavy caffeine drinker (> 5 cups or glasses of caffeinated beverages [e.g., coffee tea, cola, energy drinks] per day) within 3 months prior to screening.
5. Heavy alcohol drinker (more than 30 gram alcohol per day within 3 months prior to screening (30 gram alcohol is approximately equivalent to: i.e. 100ml of aperitif, 300ml of wine or 500ml of beer)).
6. Any clinically significant above normal range of prothrombin time, activated partial thromboplastin time, or international normalized ratio or below normal range of Protein C or Protein S laboratory result at Screening.
7. Documented history of bleeding diathesis, coagulopathy, or inherited disorders of coagulation.
8. Evidence of active bleeding, including but not limited to bleeding ulcer, bleeding gums, urinalysis positive for more than trace blood at Screening and presence of occult blood in the stool at Screening.
9. Subjects with a QTcB interval (QT interval corrected for heart rate according to Bazett's formula) > 450 msec at Screening, confirmed by a repeat assessment.
10. Conditions predisposing to QT prolongation including pathological Q-wave (defined as Q-wave >40 msec or depth > 0.4-0.5 mV).
11. History or presence of cardiac abnormalities or congenital long QT syndrome based on the final investigators' judgment.
12. History or presence of malignancy within the past 2 years, with the exception of adequately treated localized skin cancer (basal cell or squamous cell carcinoma) or carcinoma in-situ of the cervix.
13. Participation in a previous clinical trial within 3 months prior to Screening.
14. Clinically significant surgical procedure within 3 months prior to Screening.
15. Clinically significant blood loss or blood donation > 550 ml within 3 months prior to Day 1.
16. Any laboratory results from complete blood picture suspicious of ongoing blood loss.
17. Taking any prescription medication 14 days prior to Day -1.
18. Routine or as needed consumption of medications, herbal, vitamins or hormone supplements 14 days prior to Day -1 or subject is unable to withhold these medications due to underlying clinical conditions, or unwilling to refrain from taking these medications, during the study period (Day -1 to Day 15).
19. Known allergy or hypersensitivity to warfarin or the investigational product.
20. Any other conditions or clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during Screening that, in the opinion of the Principal Investigator would make the subject unsuitable for the study or put them at additional risks.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: Non-Randomized
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Tecarfarin 10mg	Drug: Tecarfarin 10mg; Tecarfarin 10mg tablets
Experimental: Tecarfarin 20mg	Drug: Tecarfarin 20mg; two tecarfarin 10mg tablets
Experimental: Tecarfarin 30mg	Drug: Tecarfarin 30mg; three tecarfarin 10mg tablets
Experimental: Tecarfarin 40mg	Drug: Tecarfarin 40mg; four tecarfarin 10mg tablets

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Adverse Events Frequency	15 Days
Adverse Events Severity	15 Days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Area under the plasma concentration versus time curve		336 Hours
Peak Plasma Concentration		336 Hours
Time which Peak Plasma Concentration is Reached		336 Hours
Elimination Rate Constant		336 Hours
Elimination Half Life		336 Hours
Clearance		336 Hours
Volume of Distribution		336 Hours
International Normalized Ratios		0 hour, 1 hour, 4 hours, 8 hours,12 hours, day 2, day 3, day 4, day 8, day 15
Prothrombin Time		0 hour, 1 hour, 4 hours, 8 hours,12 hours, day 2, day 3, day 4, day 8, day 15
Activated Partial Thromboplastin Time		0 hour, 1 hour, 4 hours, 8 hours,12 hours, day 2, day 3, day 4, day 8, day 15
Coagulation Factor II	0 hour, 1 hour, 4 hours, 8 hours,12 hours, day 2, day 3, day 4, day 8, day 15	8 Days
Coagulation Factor VII	0 hour, 1 hour, 4 hours, 8 hours,12 hours, day 2, day 3, day 4, day 8, day 15	8 Days
Coagulation Factor X	0 hour, 1 hour, 4 hours, 8 hours,12 hours, day 2, day 3, day 4, day 8, day 15	8 Days

Collaborators and Investigators

• Sponsor: Lee's Pharmaceutical Limited
• Investigators: Principal Investigator: Jo Jo SH Hai, MBBS, Queen Mary Hospital, Hong Kong

Study record dates

Study Major Dates

• Study Start (Actual): June 22, 2018
• Primary Completion (Actual): October 28, 2019
• Study Completion (Actual): October 28, 2019

Study Registration Dates

• First Submitted: August 28, 2018
• First Submitted That Met QC Criteria: August 28, 2018
• First Posted (Actual): August 29, 2018

Study Record Updates

• Last Update Posted (Actual): November 21, 2019
• Last Update Submitted That Met QC Criteria: November 20, 2019
• Last Verified: September 1, 2019

More Information

Terms related to this study

• Other Study ID Numbers: LP-HK-001

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No